Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?
COVID-19를 포함한 인간 코로나바이러스 감염의 면역병리학적 낙진 이해: 류마티스 전문의의 길을 건너게 될까요?
Review
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
Anakinra
antibody
antiphospholipid antibodies
antiviral agent
Antiviral agents
autoantibodies
Autoimmune
Autoimmunity
catastrophic
cellular entry
clinical trials
Comparisons
coronavirus
coronavirus disease
Coronavirus disease 2019
Coronavirus infection
COVID-19
COVID-19 infection
Critical
critical patients
cross
cytokine
Cytokine storm
develop
disease-modifying anti-rheumatic drug
effective
Efficacy
fatal disease
Gender
HCQ
Hydroxychloroquine
hydroxychloroquine (HCQ)
IFN
Immunomodulatory agents
immunopathological
in sight
include
individual
Infection
interferon
interferons
lupus erythematosus
male
management
mechanism
mechanism of action
metabolic syndrome
Older age
pandemic
patients with COVID-19
recent
reported
respiratory
rheumatic disease
Rheumatic diseases
risk
SARS-CoV-2
SARS-COV-2 infection
Severe acute respiratory syndrome
severe acute respiratory syndrome Coronavirus
severe acute respiratory syndrome coronavirus 2
sight
Signaling
SLE
syndrome
systemic lupus erythematosus
systemic lupus erythematosus (SLE).
Tocilizumab
Treatment
Trigger
triggers
Type I IFN
type I interferon
type I interferons
understanding
Vaccine
versed
[DOI] 10.1111/1756-185X.13909 PMC 바로가기 [Article Type] Review
[DOI] 10.1111/1756-185X.13909 PMC 바로가기 [Article Type] Review